SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024210
Filing Date
2022-11-10
Accepted
2022-11-10 09:07:04
Documents
65
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-20220930.htm   iXBRL 10-Q 2498798
2 EX-31.1 inzy-ex31_1.htm EX-31.1 22545
3 EX-31.2 inzy-ex31_2.htm EX-31.2 22734
4 EX-32.1 inzy-ex32_1.htm EX-32.1 12451
5 EX-32.2 inzy-ex32_2.htm EX-32.2 12658
  Complete submission text file 0000950170-22-024210.txt   8847047

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT inzy-20220930_def.xml EX-101.DEF 188307
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20220930.xsd EX-101.SCH 45786
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT inzy-20220930_cal.xml EX-101.CAL 42305
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20220930_lab.xml EX-101.LAB 444824
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20220930_pre.xml EX-101.PRE 339790
59 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20220930_htm.xml XML 1678268
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 221375241
SIC: 2834 Pharmaceutical Preparations